Analysis of spontaneous reporting of suspected adverse drug reactions for non-analgesic over-the-counter drugs from 2008 to 2017

被引:0
作者
Josipa Bukic
Doris Rusic
Petar Mas
Deni Karabatic
Josko Bozic
Ana Seselja Perisin
Dario Leskur
Darko Krnic
Sinisa Tomic
Darko Modun
机构
[1] University of Split School of Medicine,Department of Pharmacy
[2] Agency for Medicinal Products and Medical Devices of Croatia,Department of Pathophysiology
[3] University of Split School of Medicine,undefined
来源
BMC Pharmacology and Toxicology | / 20卷
关键词
OTC drugs; Pharmacovigilance; Adverse drug reactions; Drug safety; Spontaneous reporting;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 192 条
[1]  
Hughes CM(2001)Benefits and risks of self medication Drug Saf 24 1027-1037
[2]  
McElnay JC(2012)Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany Pharmacoepidemiol Drug Saf 21 254-260
[3]  
Fleming GF(2003)Issues related to monitoring the safety of over-the-counter (OTC) medicines Drug Saf 26 1065-1074
[4]  
Eickhoff C(2018)Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis Eur J Clin Pharmacol 74 819-832
[5]  
Hammerlein A(2018)Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients Expert Opin Drug Saf 17 125-137
[6]  
Griese N(2004)Under-reporting of serious adverse drug reactions in Sweden Pharmacoepidemiol Drug Saf 13 483-487
[7]  
Schulz M(2014)A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee Drug Saf 37 1059-1066
[8]  
Bond C(2006)Under-reporting of adverse drug reactions : a systematic review Drug Saf 29 385-396
[9]  
Hannaford P(2011)Adverse drug reaction reporting in the Czech Republic 2005-2009 Int J Clin Pharm 33 683-689
[10]  
Patel TK(2018)Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey Int J Clin Pharm 40 878-889